Meeting
2014 Breast Cancer Symposium
Screening and treatment of osteoporosis in breast cancer survivors treated with aromatase inhibitors: Gap between the national guidelines and real-world practice.
Authors
Sukriti Kamboj
Guthrie/Robert Packer Hospital, Sayre, PA
Sukriti Kamboj , Sandhya Sharma , Anuradha Sethi , Aref Agheli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Local/Regional Therapy, Survivorship, and Health Policy
Track
Local/Regional Therapy,Survivorship and Health Policy
Sub Track
Survivorship
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 113)
DOI
10.1200/jco.2014.32.26_suppl.113
Abstract #
113
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI).
First Author: David B. Page
Poster
2014 ASCO Annual Meeting
Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors.
First Author: Patricia M. Sheean
Poster
2012 ASCO Annual Meeting
Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors.
First Author: Melinda Irwin
Poster
2024 ASCO Annual Meeting
Predicting completion of endocrine therapy for older patients with early-stage breast cancer.
First Author: Jerome Karp